Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer
ChiCTR1900020503Phase 2Completed
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Apr 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Peking University Shenzhen Hospital. Primary endpoint: progression-free survival. Started Apr 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR1900020503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020503.